Lianhua Qingwen
A Traditional Chinese Medicine formulation.
General information
Lianhua Qingwen is a Traditional Chinese Medicine formulation recommended as an adjunctive therapy for fatigue and fever symptomatic relief in SARS-CoV-2 patients by National Health Commission & State Administration of Traditional Chinese Medicine. Its active components include beta-carotene, kaempferol, luteolin, naringenin, quercetin and wogonin (Xia et al., 2020).
Synonyms
Lianhuaqingwen
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19
TCM Mechanism Mixed substance In silico |
in silico | 5.75 | Predicted to act on Akt1 protein kinase involved in cellular signalling (related to e. g. lung injury and viral infection response). |
Nov/03/2020 |
|
Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening
ACE2 TCM Biophysical assay Small molecule In vitro Mixed substance In silico |
in silico; in vitro biophysical assay | 7.10 | The components/human metabolites of the formulation displayed ACE2 binding and ACE2-inhibitory activity in vitro. |
Oct/10/2020 |
|
Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
TCM Moderate severity Mild severity Mixed substance Cohort study |
Patients | 1.55 | Lianhua Qingwen capsule co-administered together with arbidol was associated with shortened time to negative SARS-CoV-2 RNA test, lower serum amyloid A and CRP, and higher lymphocyte counts compared to treatment with arbidol only. Improvement of pulmonary CT findings was also noted in the patients who were given the Lianhua Qingwen formulation. Sample size: 68 (arbidol + lianhua qingwen) + 40 (arbidol only). Dosage: 1400 mg every 8 hours for 5 to 21 days. |
Jan/29/2021 |
AI-suggested references
Clinical trials
| ID | Title | Status | Phase | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04433013 | A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19 | Withdrawn | Phase 3 | Jul/01/2020 | Feb/01/2021 |
|
|||||
